Leading heart analysts have released new guidelines on cholesterol on Saturday that urges physicians to adapt to individual patient risk assessment and recommends using two new types of drugs for people with the highest risk of the disease.
Offers are made Guidelines issued in 2013 radically change the health care provider's ability to detect the risk of cardiovascular disease and cardiovascular disease. Experts have asked doctors to track the overall matrix of patients trying to predict patients' cholesterol numbers down to specific goals and to predict their future problems.
New guidelines give doctors a better understanding of how to do this, depending on the level of cholesterol and when needed, depending on other types of tests. The 121-page document was published on Saturday in the 2018 American Scientific Heart Association's Chicago Scientific Conference and published in the Circulation magazine of the American Society of Cardiology and Heart Association magazine.
"We generally approve and broaden the scope of the threats," said Neil John, a cardiologist and co-chairman of the Northwestern University School of Medicine at the Weinberg Medical School.
For example, statin therapy is recommended for people over the age of 75 who have atherosclerotic cardiovascular disease to reduce low density lipoprotein (LDL) or 'bad' cholesterol (50%). In patients aged 40-75 with normal diabetes mild statin therapy, "moderate intensity" is shown on a different recommendation, irrespective of the patient's 10-year illness.
Heart disease is the main killer of Americans. All American adults have LDL levels of more than a third, which is the main cause of fatty deposits in the arteries leading to heart attacks, stroke and other cardiovascular diseases.
The new recommendations reaffirm the basic principles of cardiovascular disease, which should be "the lowest priority" to LDLs and the first to achieve children's healthy lifestyle. This includes diet and exercise, blood pressure monitoring, and smoking cessation.
When these steps are insufficient, the instructions reinforce the statins as the foundation of prophylactic treatment for people at risk of developing a disease. About 43 million people in the United States receive statins to reduce LDL levels. The drugs are calculated by reducing the risk of heart attack and stroke.
Since the release of the latest guidelines in 2013, two preparations have been developed and the panels have approved their use in the event that statins are insufficient. For those who suffer a heart attack or who have been exposed to many hazards, experts recommend adding Ezetemba. The drug that is sold as a zetite, but available in the general form, reduces cholesterol, which is absorbed into the small intestine.
In some cases, experts recommend using PCSK9 inhibitors, stronger drugs approved by the Food and Drug Administration in 2015, which can interfere with the liver's ability to produce LDL. Initially, the drugs used to treat heart disease at early stages are expensive and physicians have suggested a method of valuing their own value.
According to the Committee's estimates, PCSK9 inhibits more than $ 150,000 per year.
When deciding on how to treat patients, doctors may find it helpful to determine how many calories in coronary arteries have been formed on the walls of certain blood vessels. They initially developed cholesterol and identified children with heart disease.